	US 12,479,903 B2
	CD5 specific T cell receptor cell or gene therapy
Antonio Pezzutto, Berlin (DE); Thomas Blankenstein, Berlin (DE); Nese Cakmak-Görür, Berlin (DE); and Elmehdi Belbaraka, Berlin (DE)
Assigned to MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, Berlin (DE); and CHARITÉ -UNIVERSITÄTSMEDIZIN BERLIN, Berlin (DE)
Appl. No. 17/621,931
Filed by MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, Berlin (DE); and CHARITÉ -UNIVERSITÄTSMEDIZIN BERLIN, Berlin (DE)
PCT Filed Jun. 30, 2020, PCT No. PCT/EP2020/068374 § 371(c)(1), (2) Date Dec. 22, 2021, PCT Pub. No. WO2021/001356, PCT Pub. Date Jan. 7, 2021.
Claims priority of application No. 19183694 (EP), filed on Jul. 1, 2019.
Prior Publication US 2022/0363732 A1, Nov. 17, 2022
Int. Cl. C07K 14/725 (2006.01); A61K 38/00 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C12N 15/113 (2010.01)

CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/4202 (2025.01); C12N 15/1138 (2013.01); A61K 38/00 (2013.01); C12N 2310/14 (2013.01)]

21 Claims

1. A nucleic acid encoding a TCR alpha chain construct (TRA) comprising a CDR1 having SEQ ID NO: 34, a CDR2 having SEQ ID NO: 35 and a CDR3 having SEQ ID NO: 36 and a TCR beta chain construct (TRB) comprising of a CDR1 having SEQ ID NO: 37, a CDR2 having SEQ ID NO: 38 and a CDR3 having SEQ ID NO: 39;

wherein the TCR alpha chain construct and the TCR beta chain construct are encoded on the same or different nucleic acids; and wherein the TRA and TRB form a TCR construct specific for an epitope in complex with a human MHC I molecule, wherein the epitope is an epitope from human CD5; wherein the MHC I is HLA-A*02 and the epitope is SEQ ID NO: 33.